Comparison of the effects of propofol and granisetron on headache and nausea with propopofol and metoclopramide

Comparison of propofol and granistron with propopofol and metoclopramide in the treatment of pain and nausea in patients with acute migraine referred to the emergency department

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201003048903N2

Enrollment

Registered

2020-12-12

Start date

2019-09-28

Completion date

Unknown

Last updated

2021-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Migraine. Migraine

Interventions

Intervention 1: Intervention group: Group 1 patients receiving 2 mg IV bolus granistron and 1% propofol with a bolus dose of 10 mg every 5 to 10 minutes up to a maximum dose of 80 mg. Intervention 2:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: No pregnancies No breastfeeding for mothers No head trauma in the last 3 months Absence of pathological findings from neurology Interest in participating in the study Health or loss of hearing or verbal deficiency

Exclusion criteria

Exclusion criteria: Patients who need medication or action other than routine care during surgery to relieve complications and reduce pain. Instability of hemodynamic status Dissatisfaction to continue research

Design outcomes

Primary

Measure	Time frame
Headache. Timepoint: Patients' headache was measured before drug injection, 30, 45 and 60 minutes after referee injection. Method of measurement: Patients' headache rate was measured using a visual pain scale.;Nausea and vomiting. Timepoint: Nausea and vomiting referee was measured 60 minutes after drug injection. Method of measurement: It was measured and graded by a nurse or physician. (0=patients without nausea and vomiting, 1=mild nausea without treatment, 2=nausea that can be relieved with anti-nausea drug, 3 Eliminates nausea, 4=nausea or vomiting that does not respond to anti-nausea.).	—

Measure

Time frame

Headache. Timepoint: Patients' headache was measured before drug injection, 30, 45 and 60 minutes after referee injection. Method of measurement: Patients' headache rate was measured using a visual pain scale.;Nausea and vomiting. Timepoint: Nausea and vomiting referee was measured 60 minutes after drug injection. Method of measurement: It was measured and graded by a nurse or physician. (0=patients without nausea and vomiting, 1=mild nausea without treatment, 2=nausea that can be relieved with anti-nausea drug, 3 Eliminates nausea, 4=nausea or vomiting that does not respond to anti-nausea.).

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactEsmaeal Rayat Dost

Jahrom University of Medical Sciences

e.rayat.dost@gmail.com+98 71 5433 6085

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026